LINC00511 and prostate carcinoma: After LINC00673 silencing was found to be able to inhibit prostate cancer cell proliferation, the focus of the current study was shifted to determine the effects of LINC00673 on drug resistance of prostate cancer cells with DU145 and paclitaxel‐resistant DU145 cells receiving si‐NC or si‐LINC00673 treatment.